Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Advanced Colorectal Cancer|Metastatic Colorectal Cancer
DRUG: MRTX849|BIOLOGICAL: Cetuximab|DRUG: mFOLFOX6 Regimen|DRUG: FOLFIRI Regimen
Overall Survival (OS), Defined as time from date of randomization to date of death due to any cause., 30 months|Progression-free Survival (PFS), Defined as time from randomization until disease progression or death from any cause, whichever occurs first., 30 months
Adverse Events, Defined as number of patients with treatment emergent AEs., 30 months|Objective Response Rate (ORR), Defined as the percent of patients documented to have a confirmed CR or PR., 30 months|Duration of Response (DOR), Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first., 30 months|Patient Reported Outcomes (PROs), To be assessed by European Quality of Life Questionnaire for Cancer Patients (QLQ-C30)., 30 months|Quality of Life Assessment, To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L)., 30 months
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.